Blair William & Co. IL Decreases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Blair William & Co. IL lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 21.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 727,533 shares of the medical research company’s stock after selling 193,243 shares during the period. Blair William & Co. IL’s holdings in Edwards Lifesciences were worth $67,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. 9258 Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 24.8% during the 4th quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock worth $803,000 after acquiring an additional 2,093 shares in the last quarter. Gryphon Financial Partners LLC lifted its holdings in shares of Edwards Lifesciences by 35.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 6,454 shares of the medical research company’s stock valued at $492,000 after purchasing an additional 1,698 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Edwards Lifesciences by 5.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,172,836 shares of the medical research company’s stock worth $89,433,000 after purchasing an additional 58,442 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Edwards Lifesciences by 2.9% during the 4th quarter. Janney Montgomery Scott LLC now owns 76,614 shares of the medical research company’s stock worth $5,842,000 after buying an additional 2,126 shares during the last quarter. Finally, Great Lakes Advisors LLC increased its position in Edwards Lifesciences by 4.5% during the 4th quarter. Great Lakes Advisors LLC now owns 14,150 shares of the medical research company’s stock valued at $1,079,000 after buying an additional 611 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,250 shares of company stock valued at $1,218,138. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $67.22 on Wednesday. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The business has a 50-day moving average price of $71.41 and a 200 day moving average price of $83.22. The firm has a market cap of $40.51 billion, a PE ratio of 28.97, a P/E/G ratio of 2.85 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the prior year, the company earned $0.66 EPS. The firm’s revenue was up 6.7% compared to the same quarter last year. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on EW. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. JPMorgan Chase & Co. downgraded shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $105.00 to $72.00 in a research report on Thursday, July 25th. Canaccord Genuity Group decreased their price target on shares of Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Stifel Nicolaus dropped their price objective on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a report on Thursday, July 25th. Finally, Piper Sandler reduced their target price on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th. Fifteen investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $80.29.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.